"There is an urgent need for more investment in research and development for antibiotic-resistant infections including tuberculosis, otherwise we will be forced back to a time when people feared common infections and risked their lives from minor surgery", Dr. Ghebreyesus stressed.
"However, these new treatments will add little to the already existing arsenal and will not be sufficient to tackle the impending antimicrobial resistance threat".
The WHO has also identified 12 classes of priority pathogens - some of them causing common infections like pneumonia or urinary tract infections - that are increasingly resistant to antibiotics and urgently need new treatments. Most of the drugs now in the clinical pipeline are just the adjustment of existing classes of antibiotics and provide the short-term solutions to diseases.The report found very few potential treatment options for those antibiotic-resistant infections identified by WHO as greatest threat to health, which includes drug-resistant tuberculosis.
The report found very few potential treatment options for those antibiotic-resistant infections identified by WHO as posing the greatest threat to health, including drug-resistant tuberculosis which kills around 250,000 people each year.
The United Nations health agency has aired its concerns about antibiotic resistance, which makes it more hard to treat infections, for some time.
Amidst the preeminent pathogens is drug-resistant tuberculosis which eliminates about 250000 people all over the world each year and an assortment of multi drug resistant strains - Acinetobacter, Pseudomonas and various Enterobacteriaceae - which are accountable for contamination in hospitals and nursing homes and also among patients who require ventilators and catheters.
In their newly published report, the organization notes that only 51 new antibiotics and 11 biologicals are in clinical development. An example of this drug-resistant tuberculosis, a disease for which no drug has yet been developed. We've made good progress in getting this on the political agenda.
Last year, the United Nations raised the issue of antibiotic-resistant bacteria to crisis level, calling the situation "a fundamental, long-term threat to human health, sustainable food production, and development".
To counter this threat, World Health Organization and the Drugs for Neglected Diseases Initiative (DNDi) set up the Global Antibiotic Research and Development Partnership.
Researchers are working on new antibiotics, but so far, few are good enough to add to the existing antibiotic treatment stockpiles.
The agency also singled out gram-negative pathogens Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacteriaceae, including Klebsiella pneumoniae and Escherichia coli, as "the most critical priority for antibiotic research and development" because "strains are emerging worldwide that can not be treated with any of the antibiotics now on the market".